Wednesday, July 26, 2017 4:15:36 PM
Oxford Biomedica has the ability to deliver the next blockbuster, how to deliver virus to T-cells in the patient directly without the need for isolating, transforming and amplifying the cells ex-vivo.
the interests of Vulpes investors and indeed all shareholders, will be protected against the threat of either unwise dilution or indeed, the threat of a takeover approach at an unreasonably low valuation. Given OXB’s unmatched gene therapy and lentivector expertise and it’s very strong patent protected IP for gene therapy manufacturing, we see OXB has a very attractive target for acquisition in a world with a growing shortage of biologics manufacturing.
HTTP://www.vulpesinvest.com/wp-content/uploads/2017/07/VLSF%20Special%20Report_Oxford%20BioMedica%20_July_2017.pdf
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM